STOCK TITAN

Immuron Limited - IMRN STOCK NEWS

Welcome to our dedicated news page for Immuron (Ticker: IMRN), a resource for investors and traders seeking the latest updates and insights on Immuron.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immuron's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immuron's position in the market.

Rhea-AI Summary
Immuron Limited (ASX: IMC; NASDAQ: IMRN) invites shareholders to attend an investor webinar on The Watchlist, featuring CEO Steven Lydeamore providing an overview and update on the business and upcoming milestones. The webinar will be held on Tuesday, 14th November, 2023, 1:00pm AEDT/10:00am AWST and can be viewed live via zoom. A recorded copy of the webinar and presentation will be available on the Company’s website following the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.18%
Tags
none
-
Rhea-AI Summary
Immuron Limited presented at AusBioInvest 2023, an Australian biopharmaceutical company. The CEO presented on October 30th, and the presentation is available on the company's website. Contact information: Steven Lydeamore, CEO, +61 (0)3 9824 5254, info@immuron.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
none
-
Rhea-AI Summary
Immuron Limited announces the enrollment of the second cohort in the Travelan® Clinical Trial to evaluate the efficacy of Travelan® in preventing infectious diarrhea caused by ETEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
Rhea-AI Summary
Immuron Limited announces record quarterly sales of Travelan®
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
none
-
Rhea-AI Summary
Immuron Limited (NASDAQ: IMRN) to present at the 16th annual Main Event on October 4th. Recent report shows record sales of Travelan and ongoing Phase 2 clinical trials with the Department of Defense.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
none
-
Rhea-AI Summary
Record monthly sales of Travelan® with AUD $1.18 M in August 2023 (7984% increase from August 2022 sales)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
none
Rhea-AI Summary
Immuron CEO to present at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.26%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
Rhea-AI Summary
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announces that CEO Steven Lydeamore will be presenting at the 17th Bioshares Biotech Summit in Hobart, Australia on July 24th. A copy of the presentation slide deck is available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
conferences
Immuron Limited

Nasdaq:IMRN

IMRN Rankings

IMRN Stock Data

15.64M
188.40M
0.12%
0.45%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Australia
Melbourne

About IMRN

immuron ltd is a publicly listed australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. immuron’s technology platform is capable of developing and producing an orally stable therapeutic as a potential ‘oral targeted therapy’ for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (nash) diabetes, colitis, arthritis, inflammatory bowel diseases (ibd), irritable bowel syndrome (ibs), liver fibrosis and other chronic disorders in which the immune system plays a key role in thier pathogenesis. these disorders represent areas of growing and unmet medical need, where oral targeted therapy drugs could offer significant advantages due to the lack of absorption and the high safety profile. immuron has one marketed product, which provides proof of concept for its oral immune technology platform, and a pipeline of products at various stages of cl